Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathways
Open Access
- 23 September 2024
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 604, 217263
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK (A28278, A12743/A21046)
- Children's Cancer and Leukaemia Group
- The Little Princess Trust
- Neuroblastoma Society
- Institute of Cancer Research
- The Institute of Cancer Research
- Biotechnology and Biological Sciences Research Council (BB/P008232/1)
This publication has 98 references indexed in Scilit:
- m6A-modification of cyclin D1 and c-myc IRESs in glioblastoma controls ITAF activity and resistance to mTOR inhibitionCancer Letters, 2023
- 456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumorsAnnals of Oncology, 2022
- Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant GliomaCancer Cell, 2017
- Emerging roles of hnRNPA1 in modulating malignant transformationWIREs RNA, 2017
- MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastomaCancer Letters, 2016
- Functional interactions among members of the MAX and MLX transcriptional network during oncogenesisBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2015
- Deregulated Myc Requires MondoA/Mlx for Metabolic Reprogramming and TumorigenesisCancer Cell, 2015
- ATF4 and N‐Myc coordinate glutamine metabolism in MYCN‐amplified neuroblastoma cells through ASCT2 activationThe Journal of Pathology, 2014
- Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastomaPediatric Blood & Cancer, 2007
- Function of conserved domains of hnRNP A1 and other hnRNP A/B proteins.The EMBO Journal, 1994